Available Technologies
# of Displayed Technologies: 3 / 3
Applied Category Filter (Click To Remove): Oncology
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
